Loading...
XHKG0399
Market cap50mUSD
Jan 03, Last price  
0.21HKD
1D
0.94%
1Q
1.90%
Jan 2017
-64.92%
IPO
-86.33%
Name

Innovative Pharmaceutical Biotech Ltd

Chart & Performance

D1W1MN
XHKG:0399 chart
P/E
3.77
P/S
59.15
EPS
0.06
Div Yield, %
0.00%
Shrs. gr., 5y
11.28%
Rev. gr., 5y
-18.72%
Revenues
7m
-18.35%
29,061,00032,028,00083,111,000317,041,000374,442,000483,947,00090,193,00025,475,00010,050,00036,184,50033,976,00019,908,0009,187,00015,811,00018,589,00014,580,00015,189,00011,145,0008,075,0006,593,000
Net income
103m
P
-40,997,000-52,953,000-64,052,000-68,621,000745,205,00011,262,0005,247,000-123,882,000-72,839,000-569,300,500-451,684,000-236,865,000-169,788,000-231,048,000-260,272,000-407,562,000-395,752,000296,538,000-245,698,000103,403,000
CFO
-8m
L-53.07%
03,389,0003,492,0003,458,000-46,716,000-39,507,00067,645,000-25,250,000-37,436,000-67,204,000-35,571,000-133,085,000120,035,000-14,920,000-29,492,000-36,224,000-25,006,000-12,335,000-17,640,000-8,279,000
Dividend
Dec 10, 20030.02 HKD/sh

Profile

Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trading of beauty equipment and products in the People's Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, and Research and Development. It is also involved in the securities investment; research, development, and commercialization of oral insulin products; distribution of bio-industrial products; and provision of genetic testing services. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.
URL
http://www.ipb.asia/
IPO date
Jul 18, 2008
Employees
22
Domiciled in
HK
Incorporated in
BM

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
6,593
-18.35%
8,075
-27.55%
11,145
-26.62%
Cost of revenue
20,093
29,006
35,580
Unusual Expense (Income)
NOPBT
(13,500)
(20,931)
(24,435)
NOPBT Margin
Operating Taxes
(8,973)
(260,107)
Tax Rate
NOPAT
(13,500)
(11,958)
235,672
Net income
103,403
-142.09%
(245,698)
-182.86%
296,538
-174.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
336,459
1,094,287
41,881
Long-term debt
671,991
97,410
902,807
Deferred revenue
Other long-term liabilities
Net debt
1,005,375
1,190,366
940,605
Cash flow
Cash from operating activities
(8,279)
(17,640)
(12,335)
CAPEX
Cash from investing activities
(1,000)
Cash from financing activities
10,321
14,921
7,298
FCF
(10,090)
3,360
239,246
Balance
Cash
3,075
1,331
4,083
Long term investments
Excess cash
2,745
927
3,526
Stockholders' equity
(1,457,099)
950,278
959,275
Invested Capital
2,784,980
1,330,364
1,333,579
ROIC
17.62%
ROCE
EV
Common stock shares outstanding
2,498,515
1,464,193
1,750,193
Price
0.20
34.23%
0.15
-40.16%
Market cap
292,839
12.29%
260,779
-28.47%
EV
4,347,851
3,829,320
EBITDA
(12,559)
(19,050)
(22,305)
EV/EBITDA
Interest
218,097
233,969
189,951
Interest/NOPBT